Last updated on October 2018

A Multiple Dose Dose Escalation Trial of AEB1102 in Patients With AML or MDS

Brief description of study

This is the first study of the safety of increasing dose levels of AEB1102 in patients with Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome. The study will also evaluate the amounts of AEB1102 in blood, the effects of AEB1102 on blood amino acid levels and the antitumor effects of AEB1102.

Clinical Study Identifier: NCT02732184

Contact Investigators or Research Sites near you

Start Over

Dale Bixby, MD

Comprehensive Cancer Center at University of Michigan
Ann Arbor, MI United States

Geoffrey Uy, MD

Washington University Medical School
Saint Louis, MO United States

Benjamin Tomlinson, MD

University Hospitals Case Medical Center
Cleveland, OH United States

Hetty Carraway, MD

The Cleveland Clinic
Cleveland, OH United States

Michael Savona, MD

Vanderbilt-Ingram Cancer Center
Nashville, TN United States

Yair Levy, MD

Baylor Scott & White
Dallas, TX United States

Robert Collins, MD

University of Texas Southwestern Medical Center
Dallas, TX United States

Joseph Brandwein, MD

University of Alberta
Edmonton, AB Canada

Aaron Schimmer, MD

Princess Margaret Cancer Centre
Toronto, ON Canada

Sarit Assouline, MD

Jewish General Hospital
Montreal, QC Canada

Recruitment Status: Closed

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.